Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. (30th September 2016)

• Record Type: Journal Article
• Authors: Arachchillage, D. R. J.; Mackie, I. J.; Efthymiou, M.; Chitolie, A.; Hunt, B. J.; Isenberg, D. A.; Khamashta, M.; Machin, S. J.; Cohen, H.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 14:Number 11(2016:Nov.)
• Page Start: 2177
• Page End: 2186
• Publication Date: 2016-09-30
• Subjects: anaphylatoxins -- antiphospholipid syndrome -- complement -- rivaroxaban -- venous thromboembolism -- warfarin; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.13475
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials Complement activation has a pathogenic role in thrombotic antiphospholipid syndrome (APS). Coagulation proteases such as factor Xa can activate complement proteins. Complement activation markers were elevated in anticoagulated thrombotic APS patients. Complement activation decreased in APS patients switching from warfarin to rivaroxaban. Summary: Background: Complement activation may play a major role in the pathogenesis of thrombotic antiphospholipid syndrome (APS). Coagulation proteases such as factor Xa can activate complement proteins. Aims: To establish whether rivaroxaban, a direct factor Xa inhibitor, limits complement activation compared with warfarin in APS patients with previous venous thromboembolism (VTE). Methods: A total of 111 APS patients with previous VTE, on warfarin target INR 2.5, had blood samples taken at baseline and at day 42 after randomization in the RAPS (Rivaroxaban in Antiphospholipid Syndrome) trial. Fifty‐six patients remained on warfarin and 55 switched to rivaroxaban. Fifty‐five normal controls (NC) were also studied. Markers of complement activation (C3a, C5a, terminal complement complex [SC5b‐9] and Bb fragment) were assessed. Results: APS patients had significantly higher complement activation markers compared with NC at both time‐points irrespective of the anticoagulant. There were no differences between the two patient groups at baseline, or patients remaining on warfarin at day 42. In 55 patients randomized to rivaroxaban, C3a, C5a and SC5b‐9 were lower at day 42 (median (ng mL −1 ) [confidence interval] 64 [29–125] vs. 83 [35–147], 9 [2–15] vs. 12 [4–18] and 171 [56–245] vs. 201 [66–350], respectively) but levels of Bb fragment were unchanged. There were no correlations between rivaroxaban levels and complement activation markers. Conclusions: APS patients with previous VTE on warfarin exhibit increased complement activation, which is likely to occur via the classical pathway and is decreased by rivaroxaban administration. Rivaroxaban may therefore potentially provide an additional benefit to its anticoagulant effect in this patient group by limiting complement activation.